Platinum neurotoxicity: Clinical profiles, experimental models and neuroprotective approaches

Journal of Inorganic Biochemistry

Volumn 77, Issue 1-2, 1999, Pages 105-110

  Screnci, Daniela ^a   McKeage, Mark J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Neuroprotective approaches; Platinum neurotoxicity

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; AMIFOSTINE; BASIC FIBROBLAST GROWTH FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CARBOPLATIN; CILIARY NEUROTROPHIC FACTOR; CISPLATIN; CYCLOPHOSPHAMIDE; DIETHYLDITHIOCARBAMIC ACID; DIMESNA; ETOPOSIDE; GLUTATHIONE; IPROPLATIN; LOBAPLATIN; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; NIMODIPINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; SATRAPLATIN; SEBRIPLATIN; TETRAPLATIN; THIOL DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZENIPLATIN;

DRUG INDUCED DISEASE; HUMAN; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; SPINAL GANGLION; TUMOR CELL CULTURE;

EID: 0033367428     PISSN: 01620134     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-0134(99)00135-X     Document Type: Article

References (76)

1. Einhorn L.H. Clin. Cancer Res. 3:1997;2630-2632.
2. McGuire W.P., Ozols R.F. Semin. Oncol. 25:1998;340-348.
3. Thomas G.M. N. Engl. J. Med. 340:1999;1198-1200.
4. R.L. Comis, in: A.W. Prestayko, S.T. Crooke, S.K. Clarke (Eds.), Cisplatin: Current Status and New Developments, Academic Press, Orlando, FL, 1980, pp. 485-494.
5. Del Favero A., Roila F., Tonato M. Drug Saf. 9:1993;410-428.
6. Gerritsen van der Hoop R., van der Burg M.E.L., Ten Bokkel Huinink W.W., Houwelingen J.C., Neijt J.P. Cancer. 66:1990;1697-1702.
7. Thompson S.W., Davies L.E., Kornfeld M., Hilgers R.D., Standefer J.C. Cancer. 54:1984;1269-1275.
8. Roelofs R.I., Hrushesky W., Rogin J., Rosenberg L. Neurology. 34:1984;934-938.
9. Ozols R.F., Young R.C. Semin. Oncol. 12:1985;21-30.
10. Hovestadt A., van der Berg M.E., Verbiest H.B., van Putten W.L., Vecht C.J. J. Neurol. 239:1992;143-146.
11. Grunberg S.M., Sonka S., Stevenson L.L., Muggia F.M. Cancer Chemother. Pharmacol. 25:1989;62-64.
12. Bisset D., Kunkeler L., Zwanenberg L., Paul J., Gray C., Swan I.R.C., Kerr D.J., Kaye S.B. Br. J. Cancer. 62:1990;655-659.
13. Canetta R., Rozencweig M., Carter S.K. Cancer Treat. Rev. A. 12:1985;125-136.
14. Machover D., Diaz-Rubio E., de Gramont A., Schilf A., Gastiaburu J., Brienza S., Itzhaki M., Metzger G., N'Gaw D., Vignoud J. Ann. Oncol. 8:1997;604-606.
15. Extra J.M., Marty M., Brienza S., Misset J. Semin. Oncol. 25:1998;13-22.
16. Misset J. Br. J. Cancer. 77:1998;4-7.
17. Extra J. M., Espie M., Calvo F., Forme C., Mignot L., Marty M. Cancer Chemother. Pharmacol. 25:1990;299-303.
18. Levi F., Zidani R., Misset J. Lancet. 350:1997;681-686.
19. Caussanel J., Levi F., Brienza S., Misset J., Itzhaki M., Adam R., Milano G., Hecquet B., Mathe G. J. Natl. Cancer Inst. 82:1990;1046-1050.
20. O'Rourke T.J., Weiss G.R., New P., Burris H.A., Rodriquez G., Eckhart J., Hardy J., Kuhn J.G., Fields S., Clark G.M. Anticancer Drugs. 5:1998;520-526.
21. Schider R.J., La Creta F.P., Perez R.P., Johnson S.W., Brennan J.M., Rogatko A., Nash S., McAleer C., Hamilton T.C., Rody D. Cancer Res. 54:1994;709-717.
22. Trask C., Silverstone A., Ash C.M., Earl H., Irwin C., Bakker A., Tobias J.S., Souhami R.L. J. Clin. Oncol. 9:1991;1131-1137.
23. Perez-Soler R., Lopez-Berestein G., Lautersztain J., Al-Baker S., Francis K., Macias-Kiger D., Raber M.N., Khokhar A.R. Cancer Res. 50:1990;4254-4259.
24. Perez-Soler R., Shin D.M., Siddik Z.H., Murphy W.K., Huber M., Lee S.J., Khokhar A.R., Hong W.K. Clin. Cancer Res. 3:1997;373-379.
25. Willemse R.H.B., Gietema J.A., Mulder N.H., de Vries E.G.E., Meijer S., Bouma J., Birkhofer M., Rastogi R.B., Sleijfer D.Th. Eur. J. Cancer. 29A:1993;359-362.
26. Gietema J.A., Veldhuis G.-J., Guchelaar H.-J., Willemse P.H.B., Uges D.R.A., Cats A., Boonstra H., van der Graaf W.T.A., Sleijer D.Th., de Vries E.G.E., Mulder N.H. Br. J. Cancer. 71:1995;1302-1307.
27. Theriault R.L., Walters R.S., Holmes F.A., Esparza-Guerra L., Kowal C., Hortobagyi G.N. Cancer Chemother. Pharmacol. 38:1996;289-291.
28. Judson I., Cerny T., Epelbaum R., Dunlop D., Smyth J., Schaefer B., Roelvink M., Kaplan S., Hanauske A. Ann. Oncol. 8:1997;604-606.
29. Tomiwa K., Nolan C., Cavanaugh J.B. Acta Neuropathol. 69:1986;295-308.
30. de Koning P., Neijt J.P., Jennekens F.G.I., Gispen W.H. Toxicol. Appl. Pharm. 89:1987;81-87.
31. Muller L.J., Gerritsen van der Hoop R., Moore-van Delft C.M., Gispen W.H., Roubos E.W. Cancer Res. 50:1990;2437-2442.
32. Hamers F.P.T., Gerritsen van der Hoop R., Traber J., Neijt J.P., Jennekens F.G.I., Gispen W.H. Eur. J. Pharmacol. 183:1990;1710-1711.
33. Cavaletti G., Tredici G., Marmiroli P., Petruccioli M.G., Barajon I., Fabbrica D. Acta Neuropathol. 84:1992;364-371.
34. Hamers F.P.T., Brakkee J.H., Cavaletti E., Tedeschi M., Pezzoni L., Neijt J.P., Gispen W.H. Cancer Res. 53:1993;544-549.
35. Hamers F.P.T., Pette C., Bravenboer B., Vechet C.J., Neijt J.P., Gipsen W.H. Cancer Chemother. Pharmacol. 32:1993;162-166.
36. Hamers F.P.T., Gerritsen van der Hoop R., Steerenberg P.A., Neijt J.P., Gipsen W.H. Toxicol. Appl. Pharmacol. 111:1991;514-522.
37. McKeage M.J., Boxall F., Jones M., Harrap K.R. Cancer Res. 54:1994;629-631.
38. Gao W., Dybdal N., Shinsky N., Murnane A., Schmelzer C., Siegal M., Keller A., Hefti F., Phillips H.S., Winslow J.W. Ann. Neurol. 38:1995;30-37.
39. Holmes J., Stanko J., Varchenko M., Ding H., Madden V.J., Bagnell C.R., Wyriek S.D., Chaney S.C. Toxicol. Sci. 46:1998;342-351.
40. Boyle F.M., Wheeler H.R., Shenfield G.M. J. Neuro-Oncol. 41:1999;107-116.
41. Apfel S.C., Arezzo J.C., Lipson L.A., Kessler J.A. Ann. Neurol. 31:1992;76-80.
42. Krarup-Hansen A., Fuglenholm K., Helweg-Laren S., Hauge E.N., Schmalbruch H., Trojaborg W., Krarup C. Brain. 116:1993;1017-1041.
43. van Hennik M.B., van der Vijgh W.J. F., Klein I., Elferink F., Vermorken J.B., Winograd B., Pinedo H.M. Cancer Res. 47:1987;6297-6301.
44. Screnci D., Galettis P., Baguley B.C., McKeage M.J. Atomic Spectrosc. 19:1998;172-175.
45. Gregg R.W., Molepa J.M., Monpetit V.J.A., Mikael N.Z., Redmond D., Gadia M., Stewart D.J. J. Clin. Oncol. 10:1992;795-803.
46. Screnci D., Er H.M., Hambley T.W., Galettis P., Brouwer W., McKeage M.J. Br. J. Cancer. 76:1997;502-510.
47. Muller L.J., Moore-van Delft C.M., Roubos E.R., Vermorken J.B., Boer H.H. Cancer Res. 52:1992;963-973.
48. Blisard K.S., Rogers S.L., Alexander S., Harrington D.A. J. Exp. Pathol. 6:1992;65-74.
49. Malgrange B., Delree P., Rigo J.M., Baron H., Moonen G. J. Neurosci. Methods. 53:1994;111-122.
50. Windebank A.J., Smith A.G., Russell J.W. Neurology. 44:1994;488-494.
51. Konings P.N.M., Makkink W.K., van Delft A.M.L., Ruigt G.S.F. Brain Res. 640:1994;195-204.
52. Scott R.H., Woods A.J., Lacey M.J., Fernando D., Crawford J.H., Andrews P.L.R., Arch N.-S. Pharmacology. 352:1995;247-255.
53. Gill J.S., Windebank A.J. J. Clin. Invest. 101:1998;2842-2850.
54. Luo F.R., Wyriek S.D., Chaney S.G. Cancer Chemother. Pharmacol. 44:1999;29-38.
55. Kopf-Maier P., Merker H.-J. Teratology. 28:1983;189-199.
56. Mares V., Scherini E., Biggiogera M., Bernocchi G. Exp. Neurol. 91:1986;246-258.
57. Konings P.M.N., Philipsen R.L.A., van der Broek J.H.M., Ruigt G.S.F. Neurosci. Lett. 178:1994;115-118.
58. Russell J.W., Windebank A.J., McNiven M.A., Brat D.J., Brimijoing W.S. Brain Res. 676:1995;258-267.
59. Geldof A.A. J. Cancer Res. Clin. Oncol. 121:1995;657-660.
60. Alberts D.S., Noel J.K. Anticancer Drugs. 6:1995;369-383.
61. Cavaletti G., Cascinu S., Venturino P., Tedeschi M., Tredici G. Anticancer Res. 16:1996;3149-3160.
62. F. Hausher, G. Cavaletti, G. Tredici, N. Oggioni, S. Spinelli, G. Pezzoni, C. Manzotti, K. Haridas, D. Reddy, M. Zhao, P. Seetharamulu, S. Yao, P. Pavan Kumar, D. Murali, M. Wu, J. Saxe, E. Cavaletti, Proc. 90th AACR, Philadelphia, PA, 1999, Abstr. 2633.
63. Gandera D.R., Natishas W.A., Adelson M.D., Lichtman S.M., Podczaski E.S., Yanovich S., Housely H.D., Braley P., Ritch P.S., Weisberg S.R., Williams L., Diasio R.B., Perez E.A., Karp D., Reich S.D., McCarroll K., Hoff J.V. J. Clin. Oncol. 13:1995;490-496.
64. Kemp G., Rose P., Lurain J., Berman M., Manetta A., Roulett B., Homesley H., Belpomme D., Glick J.H. J. Clin. Oncol. 14:1996;2102-2112.
65. Cascinu S., Cordella L., Ferro E.D., Fronzoni M., Catakino G. J. Clin. Oncol. 13:1995;569-573.
66. Smyth J.F., Bowman A., Perren T., Wilkinson P., Prescott R.J., Quinn K.J., Tedeschi M. Ann. Oncol. 8:1997;569-573.
67. Boglium G., Marzorati L., Cavaletti G., Frattola L., Hal H. J. Neurol. Sci. 13:1992;643-647.
68. Zheng J.L., Stewart R.R., Gao W.-Q. J. Neurobiol. 28:1995;330-340.
69. Gerritsen van der Hoop R., Vecht C.J., van der Burg M.E.L., Elderson A., Boogerd W., Heimans J.J., Vries E.P., van Houwelingen J.C., Jennekens F.G.I., Gispen W.H., Niejt J.P. N. Engl. J. Med. 322:1990;89-94.
70. Roberts J.A., Jenison E.L., Kim K.-M., Clarke-Pearson D., Langleben A. Gynecol. Oncol. 67:1997;172-177.
71. Cassidy J., Paul J., Soukop M., Habeshaw I., Reed N.S., Parkin D., Kaye S.B. Cancer Chemother. Pharmacol. 41:1998;161-166.
72. Peyrot V., Briand C., Crevat A., Braguer D., Chauvet-Monges A.M., Sari J.C. Cancer Treat. Rep. 67:1983;641-646.
73. Michealis M.L., Ranciat N., Chen Y., Bechtel M., Ragan R., Hepperle M., Liu Y., Georg G. J. Neurochem. 70:1998;1623-1627.
74. Burke W.J., Raghu G., Strong R. Life Sci. 55:1994;313-319.
75. Furukawa K., Mattson M.P. Brain Res. 689:1995;141-146.
76. M.J. McKeage, G.G. Haddad, P. Galettis, D. Screnci, B.C. Baguley, Oncol. Res., in press.